HN2011000072A - DERIVATIVES OF INDOL MACROCICLIC USEFUL AS INHIBITORS OF THE VIRUS OF HEPATITIS C - Google Patents

DERIVATIVES OF INDOL MACROCICLIC USEFUL AS INHIBITORS OF THE VIRUS OF HEPATITIS C

Info

Publication number
HN2011000072A
HN2011000072A HN2011000072A HN2011000072A HN2011000072A HN 2011000072 A HN2011000072 A HN 2011000072A HN 2011000072 A HN2011000072 A HN 2011000072A HN 2011000072 A HN2011000072 A HN 2011000072A HN 2011000072 A HN2011000072 A HN 2011000072A
Authority
HN
Honduras
Prior art keywords
macrociclic
hepatitis
virus
indol
derivatives
Prior art date
Application number
HN2011000072A
Other languages
Spanish (es)
Inventor
Marie Helene Vendeville Sandrine
Jean Marie Bernard Raboisson Pierre
Lin Abdellah Tahri Tse-I
Ingrid Eduard Amssoms Katie
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of HN2011000072A publication Critical patent/HN2011000072A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/18—Bridged systems

Abstract

ESTA INVENCION SE REFIERE A DERIVADOS DE INDOL MACROCICLICOS QUE TIENEN ACTIVIDAD INHIBIDORA SOBRE LA REPLICACION DEL VIRUS DE LA HEPATITIS C (HCV). TAMBIEN SE REFIERE A COMPOSICIONES QUE COMPRESNDEN ESTOS COMPUESTOS COMO INGREDIENTES ACTIVOS, ASI COMO A PROCESOS PARA PREPARAR ESTOS COMPUESTOS Y COMPOSICIONES.THIS INVENTION REFERS TO MACROCICLIC INDOL DERIVATIVES THAT HAVE INHIBITING ACTIVITY ON THE REPLICATION OF THE HEPATITIS C (HCV) VIRUS. IT ALSO REFERS TO COMPOSITIONS THAT INCLUDE THESE COMPOUNDS AS ACTIVE INGREDIENTS, AS WELL AS PROCESSES TO PREPARE THESE COMPOUNDS AND COMPOSITIONS.

HN2011000072A 2008-07-08 2011-01-07 DERIVATIVES OF INDOL MACROCICLIC USEFUL AS INHIBITORS OF THE VIRUS OF HEPATITIS C HN2011000072A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08159965 2008-07-08
EP08160254 2008-07-11
EP08161743 2008-08-04

Publications (1)

Publication Number Publication Date
HN2011000072A true HN2011000072A (en) 2013-09-01

Family

ID=40972916

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2011000072A HN2011000072A (en) 2008-07-08 2011-01-07 DERIVATIVES OF INDOL MACROCICLIC USEFUL AS INHIBITORS OF THE VIRUS OF HEPATITIS C

Country Status (32)

Country Link
US (2) US8921355B2 (en)
EP (1) EP2310396B1 (en)
JP (2) JP5426671B2 (en)
KR (1) KR101640374B1 (en)
CN (1) CN102089314B (en)
AP (1) AP2743A (en)
AR (1) AR072726A1 (en)
AU (1) AU2009267389B8 (en)
BR (1) BRPI0915887B8 (en)
CA (1) CA2729307C (en)
CL (1) CL2011000032A1 (en)
CO (1) CO6351793A2 (en)
CR (1) CR20110076A (en)
DK (1) DK2310396T3 (en)
EA (1) EA019008B1 (en)
EC (1) ECSP11010750A (en)
ES (1) ES2651038T3 (en)
HK (1) HK1155734A1 (en)
HN (1) HN2011000072A (en)
HR (1) HRP20171892T1 (en)
HU (1) HUE035244T2 (en)
IL (1) IL210086A (en)
LT (1) LT2310396T (en)
MX (1) MX2011000276A (en)
NI (1) NI201100010A (en)
NO (1) NO2310396T3 (en)
NZ (2) NZ603343A (en)
SI (1) SI2310396T1 (en)
SV (1) SV2011003796A (en)
TW (1) TWI454476B (en)
UY (1) UY31973A (en)
WO (1) WO2010003658A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0821836A2 (en) 2007-12-24 2015-06-16 Tibotec Pharm Ltd Macrocyclic indoles as inhibitors of hepatitis c virus
TWI454476B (en) * 2008-07-08 2014-10-01 Tibotec Pharm Ltd Macrocyclic indole derivatives useful as hepatitis c virus inhibitors
UA108211C2 (en) * 2009-11-04 2015-04-10 Янссен Рід Айрленд Benzimidazole imidazole derivatives
KR20130057990A (en) 2010-04-13 2013-06-03 얀센 파마슈티칼즈, 인코포레이티드 Combination of a macrocyclic inhibitor of hcv, a non-nucleoside and a nucleoside
EP2585438B1 (en) * 2010-06-24 2014-08-20 Janssen R&D Ireland PREPARATION OF 13-CYCLOHEXYL-3-METHOXY-6-[METHYL-(2-{2-[METHYL-(SULPHAMOYL)-AMINO]-ETHOXY}-ETHYL)-CARBAMOYL]-7H-INDOLO-[2,1-a]-[2]-BENZAZEPINE-10-CARBOXYLIC ACID
BR112014004963A2 (en) 2011-09-02 2017-03-21 Novartis Ag choline salt of the substituted cyclobutanedione anti-inflammatory compound
US8716275B2 (en) * 2011-10-20 2014-05-06 Bristol-Myers Squibb Company Compound for the treatment of hepatitis C
AU2013311025A1 (en) 2012-08-31 2015-02-26 Janssen Pharmaceuticals, Inc. Combination of a macrocyclic protease inhibitor of HCV, a non-nucleoside HCV inhibitor and ritonavir
WO2014152275A1 (en) * 2013-03-14 2014-09-25 Concert Pharmaceuticals, Inc. Deuterium modified derivatives of the ns5b polymerase inhibitor tmc647055
US10450263B2 (en) 2017-02-10 2019-10-22 Southern Research Institute Benzo annulenes as antiviral agents
KR101974388B1 (en) 2017-06-23 2019-05-02 (주)에니켐텍 Alkyl diethylene triamine derivatives and a process of the preparation thereof
WO2019133574A2 (en) * 2017-12-26 2019-07-04 Southern Research Institute Benzoannulene derivatives as antiviral agents

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US20050267836A1 (en) 1996-03-25 2005-12-01 Cfph, Llc Method and system for transacting with a trading application
TR199802136T2 (en) 1996-04-23 2001-06-21 Vertex Pharmaceuticals Incorporated Ire derivatives as inhibitors of the �MPDH enzyme.
AU6701598A (en) 1997-03-14 1998-09-29 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
EE200100492A (en) 1999-03-19 2002-12-16 Vertex Pharmaceuticals Incorporated IMPDH inhibitors
CN1290140C (en) 2000-08-30 2006-12-13 松下电器产业株式会社 Plasma display unit and production method thereof
JP4902361B2 (en) 2004-01-30 2012-03-21 メディヴィル・アクチエボラーグ HCVNS-3 serine protease inhibitor
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
PE20070211A1 (en) 2005-07-29 2007-05-12 Medivir Ab MACROCYCLIC COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS
AU2006286441A1 (en) 2005-09-02 2007-03-08 Janssen R&D Ireland Benzodiazepines as HCV inhibitors
US7399758B2 (en) 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
GB0522881D0 (en) 2005-11-10 2005-12-21 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2007092000A1 (en) 2006-02-06 2007-08-16 Bristol-Myers Squibb Company Inhibitors of hcv replication
US7521443B2 (en) 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7456166B2 (en) * 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
WO2007140200A2 (en) * 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
EA018935B1 (en) 2006-10-10 2013-11-29 Медивир Аб Hcv nucleoside inhibitor
CN103224506A (en) 2006-12-20 2013-07-31 P.安杰莱蒂分子生物学研究所 Antiviral indoles
WO2009010783A1 (en) * 2007-07-17 2009-01-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Macrocyclic indole derivatives for the treatment of hepatitis c infections
TWI454476B (en) 2008-07-08 2014-10-01 Tibotec Pharm Ltd Macrocyclic indole derivatives useful as hepatitis c virus inhibitors
TW201023858A (en) 2008-09-18 2010-07-01 Ortho Mcneil Janssen Pharm Synergistic combinations of a macrocyclic inhibitor of HCV and a nucleoside
CA2753667C (en) 2009-02-27 2015-11-17 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Amorphous salt of a macrocyclic inhibitor of hcv
KR20130057990A (en) 2010-04-13 2013-06-03 얀센 파마슈티칼즈, 인코포레이티드 Combination of a macrocyclic inhibitor of hcv, a non-nucleoside and a nucleoside
EP2585438B1 (en) 2010-06-24 2014-08-20 Janssen R&D Ireland PREPARATION OF 13-CYCLOHEXYL-3-METHOXY-6-[METHYL-(2-{2-[METHYL-(SULPHAMOYL)-AMINO]-ETHOXY}-ETHYL)-CARBAMOYL]-7H-INDOLO-[2,1-a]-[2]-BENZAZEPINE-10-CARBOXYLIC ACID
AU2013311025A1 (en) 2012-08-31 2015-02-26 Janssen Pharmaceuticals, Inc. Combination of a macrocyclic protease inhibitor of HCV, a non-nucleoside HCV inhibitor and ritonavir

Also Published As

Publication number Publication date
HK1155734A1 (en) 2012-05-25
MX2011000276A (en) 2011-03-02
AU2009267389A8 (en) 2013-07-04
CN102089314B (en) 2014-07-23
AU2009267389A1 (en) 2010-01-14
JP5426671B2 (en) 2014-02-26
CR20110076A (en) 2011-11-10
JP2014028818A (en) 2014-02-13
US9427440B2 (en) 2016-08-30
AU2009267389B2 (en) 2013-05-30
SV2011003796A (en) 2011-04-08
AU2009267389B8 (en) 2013-07-04
EA019008B1 (en) 2013-12-30
HRP20171892T1 (en) 2018-01-12
NO2310396T3 (en) 2018-02-03
US8921355B2 (en) 2014-12-30
WO2010003658A1 (en) 2010-01-14
US20140107101A1 (en) 2014-04-17
CA2729307A1 (en) 2010-01-14
AR072726A1 (en) 2010-09-15
IL210086A (en) 2014-05-28
KR101640374B1 (en) 2016-07-18
CN102089314A (en) 2011-06-08
EA201170153A1 (en) 2011-08-30
BRPI0915887B8 (en) 2021-05-25
AP2743A (en) 2013-09-30
EP2310396B1 (en) 2017-09-06
NZ603343A (en) 2013-08-30
SI2310396T1 (en) 2018-01-31
JP2011527299A (en) 2011-10-27
AP2010005521A0 (en) 2010-12-31
ECSP11010750A (en) 2011-08-31
NZ590073A (en) 2012-11-30
CO6351793A2 (en) 2011-12-20
TWI454476B (en) 2014-10-01
BRPI0915887B1 (en) 2020-02-18
TW201014865A (en) 2010-04-16
DK2310396T3 (en) 2017-12-11
IL210086A0 (en) 2011-02-28
BRPI0915887A2 (en) 2015-11-03
UY31973A (en) 2010-01-29
NI201100010A (en) 2011-09-07
US20110105473A1 (en) 2011-05-05
ES2651038T3 (en) 2018-01-23
HUE035244T2 (en) 2018-05-02
KR20110040889A (en) 2011-04-20
EP2310396A1 (en) 2011-04-20
LT2310396T (en) 2017-12-27
CA2729307C (en) 2017-08-29
CL2011000032A1 (en) 2011-07-15
JP5808370B2 (en) 2015-11-10

Similar Documents

Publication Publication Date Title
HN2011000072A (en) DERIVATIVES OF INDOL MACROCICLIC USEFUL AS INHIBITORS OF THE VIRUS OF HEPATITIS C
EA201000089A1 (en) APPLICATION OF HOMO- AND COPOLYMERS TO STABILIZE THE COMPOSITIONS OF ACTIVE INGREDIENTS
CR11316A (en) DERIVED FROM URACILO OR TIMINA FOR THE TREATMENT OF HEPATITIS C.
ECSP099685A (en) SULFUR COMPOUNDS AS INHIBITORS OF THE SERINA PROTEASA NS3 OF THE HEPATITIS C VIRUS
CL2016001580A1 (en) Use of indole-derived compounds to treat a flavivirus infection; indole derived compounds; pharmaceutical compositions; and use of a combination.
DOP2013000185A (en) ANTIVIRAL COMPOUNDS
GT200900027A (en) ORGANIC COMPOUNDS
EA201270555A1 (en) COMBINATION OF HEPATITIS C VIRUS INHIBITORS
CO6321189A2 (en) BENCEN-SULFONAMIDE TIAZOL AND OXAZOL COMPOUNDS
PE20151423A1 (en) TETRAHYDROPYRANIL DERIVATIVES INHIBITORS OF HCV
HN2012001162A (en) TRIAZOLOPIRIDINS
HN2010002733A (en) COMPOUNDS AND COMPOSITIONS AS CINASE INHIBITORS
CL2010001634A1 (en) Compounds derived from nucleosides, hepatitis c virus inhibitors; preparation procedure; pharmaceutical composition that includes them; and pharmaceutical combination.
CL2012001176A1 (en) Benzimidazole-imidazole derivative compounds, hepatitis c virus (hcv) inhibitors; pharmaceutical composition comprising them; pharmaceutical combination; use in the prevention or treatment of hcv infection.
HN2008001191A (en) SUBSTITUTED BICYCOLACTAM COMPOUNDS
CR20110043A (en) FUNGICIDE BLENDS THAT INCLUDE 1-METHYLPIRAZOL-4-ILCARBOXANILIDS REPLACED
CR11583A (en) INSECTICIDED ARILPIRROLINAS
NI201100056A (en) MULTIHETEROARYL COMPOUNDS AS INHIBITORS OF PROSTAGLANDIN D HEMATOPOIETIC SYNTHASE AND THEIR USE TO TREAT DISEASES MEDIATED BY PROSTAGLANDIN D2.
UY32659A (en) PIRAZINILPIRAZOLES
CL2011001364A1 (en) Compounds derived from cyclopropyl uracil nucleotides, hepatitis c virus polymerase inhibitors; pharmaceutical compositions; and use of the compound for the treatment of hepatitis c (hcv).
HN2009000566A (en) NEW DERIVATIVES OF DIOSMETINE, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT.
EA201101116A1 (en) PHARMACEUTICAL COMPOSITIONS, INCLUDING 2-OXO-1-PYRROLIDINE DERIVATIVES
EA201101118A1 (en) PHARMACEUTICAL COMPOSITIONS, INCLUDING 2-OXO-1-PYRROLIDINE DERIVATIVES
UY32721A (en) USEFUL PHARMACEUTICAL COMPOSITIONS TO TREAT HEPATITIS C (HCV) VIRUSES, USES AND RELATED METHODS
CO6321288A2 (en) SALES OF HIV INHIBITING COMPOUNDS